CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER

Breast cancer is the most common cause of death from cancer among women in Russia. More than half of patients have metastases at diagnosis. Chemotherapy is an important component of combined modality treatment for breast cancer. The budget impact analysis of expenses for the use of eribulina demonst...

Full description

Saved in:
Bibliographic Details
Main Authors: S. L. Plavinsky, P. I. Shabalkin
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2016-02-01
Series:Сибирский онкологический журнал
Subjects:
breast cancer
eribulin
budget impact analysis
Online Access:https://www.siboncoj.ru/jour/article/view/268
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items